{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T19:09:10Z","timestamp":1745953750318},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,7]]},"DOI":"10.7759\/cureus.41524","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T17:28:07Z","timestamp":1688750887000},"source":"Crossref","is-referenced-by-count":3,"title":["A Rare Presentation of Zoledronate-Induced Systemic Inflammatory Response"],"prefix":"10.7759","author":[{"given":"Maria","family":"Jamil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Daneshvar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Nachawati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Husam","family":"El Sharu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Meysami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2147\/cia.s2046","article-title":"Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women","volume":"3","author":"Lambrinoudaki I","year":"2008","unstructured":"Lambrinoudaki I, Vlachou S, Galapi F, Papadimitriou D, Papadias K. Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women. Clin Interv Aging. 2008, 3:445-51. 10.2147\/cia.s2046","journal-title":"Clin Interv Aging"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)60752-0","article-title":"Adverse effects of bisphosphonates: implications for osteoporosis management","volume":"84","author":"Kennel KA","year":"2009","unstructured":"Kennel KA, Drake MT. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc. 2009, 84:632-8. 10.1016\/S0025-6196(11)60752-0","journal-title":"Mayo Clin Proc"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake MT","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008, 83:1032-45. 10.4065\/83.9.1032","journal-title":"Mayo Clin Proc"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-010-1274-6","article-title":"Oral bisphosphonate compliance and persistence: a matter of choice?","volume":"22","author":"Silverman SL","year":"2011","unstructured":"Silverman SL, Schousboe JT, Gold DT. Oral bisphosphonate compliance and persistence: a matter of choice?. Osteoporos Int. 2011, 22:21-6. 10.1007\/s00198-010-1274-6","journal-title":"Osteoporos Int"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.837534","article-title":"Bisphosphonates targeting ion channels and musculoskeletal effects","volume":"13","author":"Scala R","year":"2022","unstructured":"Scala R, Maqoud F, Antonacci M, et al.. Bisphosphonates targeting ion channels and musculoskeletal effects. Front Pharmacol. 2022, 13:837534. 10.3389\/fphar.2022.837534","journal-title":"Front Pharmacol"},{"key":"ref6","article-title":"Zoledronate. [Updated 2023 Apr 12].","author":"Greear EL","year":"2023","unstructured":"Greear EL, Bankole A. Zoledronate. [Updated 2023 Apr 12].. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK585053\/:"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2016\/17061.7021","article-title":"Study of adverse effect profile of parenteral zoledronic acid in female patients with osteoporosis","volume":"10","author":"Kotian P","year":"2016","unstructured":"Kotian P, Boloor A, Sreenivasan S. Study of adverse effect profile of parenteral zoledronic acid in female patients with osteoporosis. J Clin Diagn Res. 2016, 10:OC04-6. 10.7860\/JCDR\/2016\/17061.7021","journal-title":"J Clin Diagn Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-009-1123-7","article-title":"Flare-up of hand osteoarthritis caused by zoledronic acid infusion","volume":"21","author":"Werner de Castro GR","year":"2010","unstructured":"Werner de Castro GR, Neves FS, de Magalh\u00e3es Souza Fialho SC, Pereira IA, Ribeiro G, Zimmermann AF. Flare-up of hand osteoarthritis caused by zoledronic acid infusion. Osteoporos Int. 2010, 21:1617-9. 10.1007\/s00198-009-1123-7","journal-title":"Osteoporos Int"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.11138\/ccmbm\/2015.12.1.069","article-title":"Severe polyarthritis secondary to zolendronic acid: a case report and literature review","volume":"12","author":"White SL","year":"2015","unstructured":"White SL, Jacob A, Gregson C, Bhalla A. Severe polyarthritis secondary to zolendronic acid: a case report and literature review. Clin Cases Miner Bone Metab. 2015, 12:69-74. 10.11138\/ccmbm\/2015.12.1.069","journal-title":"Clin Cases Miner Bone Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/0961203314559633","article-title":"Gamma-delta T lymphocytes and 25-hydroxy vitamin D levels as key factors in autoimmunity and inflammation: the case of zoledronic acid-induced acute phase reaction","volume":"24","author":"De Santis M","year":"2015","unstructured":"De Santis M, Cavaciocchi F, Ceribelli A, et al.. Gamma-delta T lymphocytes and 25-hydroxy vitamin D levels as key factors in autoimmunity and inflammation: the case of zoledronic acid-induced acute phase reaction. Lupus. 2015, 24:442-7. 10.1177\/0961203314559633","journal-title":"Lupus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-022-03695-y","article-title":"Lessons learned from long-term side effects after zoledronic acid infusion following denosumab treatment: a case report and review of the literature","volume":"16","author":"Nurmi-L\u00fcthje I","year":"2022","unstructured":"Nurmi-L\u00fcthje I, L\u00fcthje P. Lessons learned from long-term side effects after zoledronic acid infusion following denosumab treatment: a case report and review of the literature. J Med Case Rep. 2022, 16:473. 10.1186\/s13256-022-03695-y","journal-title":"J Med Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/165206-a-rare-presentation-of-zoledronate-induced-systemic-inflammatory-response","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:02:41Z","timestamp":1707508961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/165206-a-rare-presentation-of-zoledronate-induced-systemic-inflammatory-response"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.41524","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,7]]}}}